Ástralía - enska - Department of Health (Therapeutic Goods Administration)

key pharmaceuticals pty ltd - 11067 - cryosurgical unit, general-purpose - cryosurgery treatment used to freeze superficial skin lesions (eg warts and verrucas) for their destruction and removal

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

beacon pharmaceuticals ltd - streptokinase - powder for solution for infusion - 1.5mega unit

Ísrael - enska - Ministry of Health

abbvie biopharmaceuticals ltd, israel - sevoflurane - liquid for inhalation - sevoflurane 100 % - sevoflurane - sevoflurane is indicated for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

zone medical pty ltd - 11067 - cryosurgical unit, general-purpose - treat dermatological conditions via cryotherapy pen device

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

innovative medcare technology pty ltd - 11067 - cryosurgical unit, general-purpose - the cannulas are used to introduce and help position the c3 cryoprobe. the cannulas are sterile delivered disposables and are available in various dimensions depending on the type of the c3 cryoprobe.

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - sunitinib 12.5mg - capsule - 12.5 mg - active: sunitinib 12.5mg excipient: croscarmellose sodium gelatin printing ink, white iron oxide red magnesium stearate mannitol microcrystalline cellulose povidone titanium dioxide - treatment of advanced renal cell carcinoma

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - sunitinib 25mg - capsule - 25 mg - active: sunitinib 25mg excipient: croscarmellose sodium gelatin printing ink, white iron oxide black iron oxide red iron oxide yellow magnesium stearate mannitol microcrystalline cellulose povidone titanium dioxide - treatment of advanced renal cell carcinoma

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - sunitinib 37.5mg - capsule - 37.5 mg - active: sunitinib 37.5mg excipient: croscarmellose sodium gelatin printing ink, black iron oxide yellow magnesium stearate mannitol microcrystalline cellulose povidone titanium dioxide - treatment of advanced renal cell carcinoma

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - sunitinib 50mg - capsule - 50 mg - active: sunitinib 50mg excipient: croscarmellose sodium gelatin printing ink, white iron oxide black iron oxide red iron oxide yellow magnesium stearate mannitol microcrystalline cellulose povidone titanium dioxide - treatment of advanced renal cell carcinoma

Bandaríkin - enska - NLM (National Library of Medicine)

northstar rxllc - sunitinib malate (unii: lvx8n1ut73) (sunitinib - unii:v99t50803m) - sunitinib malate capsules are indicated for the treatment of adult patients with gastrointestinal stromal tumor (gist) after disease progression on or intolerance to imatinib mesylate. sunitinib malate capsules are indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc). sunitinib malate capsules are indicated for the adjuvant treatment of adult patients at high risk of recurrent rcc following nephrectomy. sunitinib malate capsules are indicated for the treatment of progressive, well differentiated pancreatic neuroendocrine tumors (pnet) in adult patients with unresectable locally advanced or metastatic disease. none risk summary based on animal reproduction studies and its mechanism of action, sunitinib can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data in pregnant women to inform a drug-associated risk. in animal developmental and reproductive toxicology studies, oral administration of sunitinib to pregna